CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that the company has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.
FierceMedicalDevices editors chose this year's winners based on their top management teams, notable financial backing, promising technologies and market opportunities. The awards were announced at an event that took place today during AdvaMed 2012: The MedTech Conference in Boston, Mass. CardioKinetix was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
“We’ll be paying detailed attention to CardioKinetix, particularly its pivotal study involving nearly 500 patients who will be testing its Parachute device to treat ischemic heart failure. The umbrella-like creation is inventive, delivered through a catheter and inserted into the femoral artery so it partitions off the heart’s damaged portion, restoring its function and shape in the process,” said FierceMedicalDevices Editor Mark Hollmer.
“We are very pleased to be included in the inaugural Fierce 15 list of leading medical device and diagnostic companies,” said Maria Sainz, president and CEO of CardioKinetix. “Following our recent presentation of three-year data at the European Society of Cardiology conference, physicians globally have expressed enthusiasm about our innovative device, which has the potential to improve the lives of thousands of patients with heart failure.”
Many heart attack survivors experience enlargement of the heart, causing a decrease in cardiac output that results in heart failure symptoms such as fatigue and shortness of breath. The healthy portion of the heart not affected by the heart attack has to compensate for the loss in output and becomes overloaded over time.
Current treatment options for patients whose hearts have enlarged are limited. The Parachute device offers the first minimally invasive catheter-based treatment to partition the damaged muscle, excluding the non-functioning, damaged heart muscle from the healthy, functional segment to decrease the overall volume of the left ventricle chamber and restore its optimal geometry and function. This minimally invasive procedure is performed in the catheterization laboratory under conscious sedation.
The Parachute Ventricular Partitioning Device received CE Mark in 2011. In the U.S., the Parachute system is an investigational device limited by federal law to investigational use only and is not available for sale.
An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and post-marketing. A complete list of "Fierce 15" companies is available online at www.fiercemedicaldevices.com.
About CardioKinetix Inc.
CardioKinetix, based in Menlo Park, Calif., is pioneering the catheter-based Parachute™ Ventricular Partitioning Device for heart failure. Privately held, the company is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q Healthcare Investors. For more information please visit www.cardiokinetix.com.Business Wire
Last updated on: 02/10/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.